Robert Flisiak
Medical University of Białystok · 632 works · 23,548 citations · h-index 55
Top works
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
- Advancing the global public health agenda for NAFLD: a consensus statement
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
- Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective
- Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
- Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
- Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†
- Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
- The present and future disease burden of hepatitis C virus ( HCV ) infections with today's treatment paradigm – volume 2
- Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients
- The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus